SGMS2 and skeletal dysplasia: In summary, our findings indicate that SGMS2 pathogenic variants impair bone material properties, resulting in disturbances in mechanical competence; development and growth of the skeleton; and underlie a spectrum of skeletal conditions, ranging from early-onset osteoporosis to osteoporosis with skeletal dysplasia.